Hyper-activation of the PI3K/mTOR pathway is known to be involved in leukemia and drug resistance.25 The gene expression data suggested an enrichment of the PI3K/mTOR pathway in the resistant cell lines, as well as in primary patient AML blasts, which are resistant to sorafenib therapy. This evidence concerns the gene MTOR and acute myeloid leukemia.